Indian Journal of Palliative Care
Open access journal 
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size Users online: 792  
     Home | About | Feedback | Login 
  Current Issue Back Issues Editorial Board Authors and Reviewers How to Subscribe Advertise with us Contact Us Analgesic Prescription  
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (304 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed119    
    Printed2    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents 
LETTER TO EDITOR
Year : 2018  |  Volume : 24  |  Issue : 4  |  Page : 547-548

Feasibility of chronotherapy for preventing delirium in patients with cancer: An idea for future clinical trials


Department of Nursing, Shahrood Branch, Islamic Azad University, Shahrood, Iran

Date of Web Publication15-Oct-2018

Correspondence Address:
Leila Radrazm
Department of Nursing, Shahrood Branch, Islamic Azad University, Shahrood
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJPC.IJPC_124_18

Rights and Permissions



How to cite this article:
Radrazm L. Feasibility of chronotherapy for preventing delirium in patients with cancer: An idea for future clinical trials. Indian J Palliat Care 2018;24:547-8

How to cite this URL:
Radrazm L. Feasibility of chronotherapy for preventing delirium in patients with cancer: An idea for future clinical trials. Indian J Palliat Care [serial online] 2018 [cited 2018 Nov 12];24:547-8. Available from: http://www.jpalliativecare.com/text.asp?2018/24/4/547/243278


Sir,

Although delirium is a widespread neuropsychiatric complication within high dependency care units such as intensive care, its prevalence is increasing in patients who suffer from end-of-life situations. It is estimated that between 20% and 85% of patients with advanced cancer experience delirium.[1] This is while over 50% of these cases are preventable and reversible.[2] The suggested factors associated with delirium in patients with advanced cancer are advanced illness, old age, opioid-induced neurotoxicity, central nervous system metastases, treatment with benzodiazepine, hematologic malignancy, sensory impairment, sleep disturbance, physical performance, cancer type, and albumin level.[1],[3]

Delirium is a multifaceted syndrome characterized as an acute change in mental status, disturbance of consciousness, speaking, and attention as well as fluctuating impairment of cognition during the course of a day.[4] A possible mechanism leading to cognitive dysfunction and delirium is neuronal dysfunction, particularly cholinergic dysfunction, due to systemic disorders, loss of circadian rhythms, and environmental-related risk factors.[5] Based on this assumed mechanism, several interventions have been designed and implemented for its prevention and treatment with heterogeneous results to date. Elimination or correction of underlying causal factors, modification of predisposing risk factors and palliative care of symptoms are the current standard approaches to treat delirium in patients with cancer.[6] However, the effectiveness of these interventions is inconclusive and at this time, a specific intervention to target delirium in patients suffering from advanced cancer remains to be defined.[3],[6] Whereas increasing evidence suggests that delirium has significant morbidity and mortality and untreated delirium can significantly impact clinical outcomes of patients with cancer.[4] Therefore, given the high prevalence rates and increased morbidity and mortality, effective preventive strategies need to be developed for reducing or treating delirium in patients with advanced cancer. In this regard, in recent years, most of the nonpharmacological interventions have focused on the restoration of the circadian rhythm in delirious patients.[7]

Chronotherapy is a therapeutic approach for purposeful modification and restoration of circadian rest-activity rhythms.[7],[8] It includes interventions such as bright light therapy, music therapy, noise control, dynamic light applications, and use of eyeshades that moderate the environmental stimuli.[7],[8] For many years, chronotherapy, in particular chronopharmacology, has been used to increase the effectiveness of cancer prevention and treatment interventions.[8] In addition, recent evidence suggests that chronotherapy, as a behavioral technique for sleep scheduling, appears to have a beneficial role in reducing the incidence of delirium within critical care.[7] However, to the best of our knowledge, no study has examined the effectiveness of chronotherapy on the reduction of delirium occurrence in cancer patients.

The research regarding the effect of chronotherapy on delirium mostly have been conducted on patients hospitalized in the intensive care units and the literature does not include any studies concerning the effect of chronotherapy on decreasing delirium incidence or preventing delirium among patients with advanced cancer. Considering the high incidence of delirium in patients with advanced cancer and potential benefits of chronotherapy on decreasing delirium incidence or preventing delirium, an interesting question arises that merits further investigation. Could chronotherapy reduce the delirium of patients with advanced cancer? However, because of inadequate evidence, the efficacy of chronotherapy is inconclusive and further research is needed. It seems that this nonpharmacological intervention can be used as an effective, inexpensive, innovative, and safe intervention for reducing the delirium. Therefore, further well-designed clinical trials are necessary to determine the effectiveness of chronotherapy on delirium in patients with advanced cancer.

Authorship statements

The author certifies that she has participated sufficiently in the work to take public responsibility for the content, including participation in the concept, writing, or revision of the manuscript.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Grandahl MG, Nielsen SE, Koerner EA, Schultz HH, Arnfred SM. Prevalence of delirium among patients at a cancer ward: Clinical risk factors and prediction by bedside cognitive tests. Nord J Psychiatry 2016;70:413-7.  Back to cited text no. 1
    
2.
Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med 2004;18:184-94.  Back to cited text no. 2
    
3.
Lawley H, Hewison A. An integrative literature review exploring the clinical management of delirium in patients with advanced cancer. J Clin Nurs 2017;26:4172-83.  Back to cited text no. 3
    
4.
Edelstein A, Alici Y. Diagnosing and managing delirium in cancer patients. Oncology (Williston Park) 2017;31:686-692, III.  Back to cited text no. 4
    
5.
Hshieh TT, Inouye SK, Oh ES. Delirium in the elderly. Psychiatr Clin North Am 2018;41:1-7.  Back to cited text no. 5
    
6.
Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012;30:1206-14.  Back to cited text no. 6
    
7.
Luther R, McLeod A. The effect of chronotherapy on delirium in critical care – a systematic review. Nurs Crit Care 2017. Doi: doi.org/10.1111/nicc.12300.  Back to cited text no. 7
    
8.
Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev 2010;62:979-1001.  Back to cited text no. 8
    




 

Top
Print this article  Email this article
Online since 1st October '05
Published by Wolters Kluwer - Medknow